SCHEMBL1763155

SCHEMBL1763155

CC(C)C(=O)[C@]1(n2ccc(N)nc2=O)C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3A Q14432 3/20 0.42
PDE4D Q08499 1/20 0.42
SLC29A1 Q99808 1/20 0.42
LMNA P02545 4/20 0.42
THRB P10828 1/20 0.42
MTOR P42345 1/20 0.42
MDM2 Q00987 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
CACNA1F O60840 2/20 0.38
ALB P02768 2/20 0.38
MAPT P10636 2/20 0.38
CACNA1D Q01668 2/20 0.38
CACNA1S Q13698 2/20 0.38
CACNA1C Q13936 2/20 0.38
POLB P06746 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 1/20 0.33
POLA1 P09884 1/20 0.32
ADRB1 P08588 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8627861 0.88 PDE3A (0.44) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL15301640 0.85 PDE3A (0.37) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL4971197 0.82 PDE3A (0.41) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL20819437 0.82 PDE3A (0.39) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL5709959 0.82 PDE3A (0.41) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL2984542 0.81 PDE3A (0.39) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL28996805 0.81 PDE3A (0.39) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL51650 0.80 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL27544566 0.80 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL992472 0.80 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8614312-B2 Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-24 US disclosed
US-20110118454-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-05-19 US disclosed
EP-2265624-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED Centre National de la Recherche Scientifique (FR) 2010-12-29 EP disclosed
WO-2009115694-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-09-24 WO disclosed
US-5204456-A Derivatives of nucleosides and their use for the synthesis of oligonucleotides COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1993-04-20 US disclosed
US-4980460-A Protected nucleosides which permit more efficient oligonucleotide syntheses COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1990-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118454-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED PNP, NUDT1, DUT PDE3A 2070/4885PDE4D 776/4885SLC29A1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.